Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis.

IF 11.6 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY

Liver Cancer Pub Date : 2024-08-28 eCollection Date: 2025-04-01 DOI:10.1159/000540291

Masashi Mizumoto, Kei Shibuya, Kazuki Terashima, Masao Murakami, Motohiro Murakami, Yoshiyuki Shioyama, Yoshiro Matsuo, Takashi Ogino, Tatsuya Ohno, Takahiro Waki, Hiroyuki Ogino, Hiroyasu Tamamura, Norio Katoh, Masaru Wakatsuki, Tomoaki Okimoto, Motohisa Suzuki, Takashi Saito, Shingo Toyama, Takayuki Hashimoto, Hisateru Ohba, Shoji Kubo, Kiyoshi Hasegawa, Kazushi Maruo, Hideyuki Sakurai

{"title":"Particle Therapy for Intrahepatic Cholangiocarcinoma: A Multicenter Prospective Registry Study, Systematic Review and Meta-Analysis.","authors":"Masashi Mizumoto, Kei Shibuya, Kazuki Terashima, Masao Murakami, Motohiro Murakami, Yoshiyuki Shioyama, Yoshiro Matsuo, Takashi Ogino, Tatsuya Ohno, Takahiro Waki, Hiroyuki Ogino, Hiroyasu Tamamura, Norio Katoh, Masaru Wakatsuki, Tomoaki Okimoto, Motohisa Suzuki, Takashi Saito, Shingo Toyama, Takayuki Hashimoto, Hisateru Ohba, Shoji Kubo, Kiyoshi Hasegawa, Kazushi Maruo, Hideyuki Sakurai","doi":"10.1159/000540291","DOIUrl":null,"url":null,"abstract":"Introduction: A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-analysis of literature data and a systematic comparison using registry data.Methods: Patients who received particle therapy for ICC from May 2016 to June 2018 were registered. Nineteen manuscripts (4 particle therapy, 8 3D-CRT, 7 SBRT) were selected for the meta-analysis.Results: A total of 85 cases (proton beam therapy 59, carbon therapy 26) were registered. The median overall survival (OS) of the 85 patients was 22.1 months (95% CI: 12.9-31.3); the 1-, 2-, 3-, and 4-year OS rates were 70.9% (95% CI: 61.1-80.7%), 47.6% (36.8-58.4%), 37.7% (26.7-48.7%), and 22.7% (10.2-35.2%), respectively; and the 1-, 2-, 3-, and 4-year local recurrence rates were 8.2% (1.1-15.3%), 21.6% (9.3-33.9%), 33.4% (16.7-50.1%), and 33.4% (16.7-50.1%), respectively. In the meta-analysis and registry data, the 1-year OS for particle therapy, SBRT and 3D-CRT were 71.8% (95% CI: 64.6-77.8%), 59.2% (53.0-64.9%, p = 0.0573), and 47.2% (36.8-56.9%, p = 0.0004), respectively. The incidence of grade 3 or higher late non-hematological toxicity in the meta-analysis and registry data were 7.4-12% for particle therapy, 6.7-16.7% for SBRT, and 8.1-14.3% for 3D-CRT.Conclusions: Particle therapy achieved a good therapeutic effect for ICC, and a meta-analysis indicated that particle therapy is a better treatment modality than SBRT and 3D-CRT.","PeriodicalId":18156,"journal":{"name":"Liver Cancer","volume":"14 2","pages":"211-222"},"PeriodicalIF":11.6000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12005709/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Liver Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000540291","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: A prospective study was started in May 2016 to evaluate the efficacy and safety of particle therapy for intrahepatic cholangial carcinoma (ICC). To compare treatment modalities, we also conducted a meta-analysis of literature data and a systematic comparison using registry data.

Methods: Patients who received particle therapy for ICC from May 2016 to June 2018 were registered. Nineteen manuscripts (4 particle therapy, 8 3D-CRT, 7 SBRT) were selected for the meta-analysis.

Results: A total of 85 cases (proton beam therapy 59, carbon therapy 26) were registered. The median overall survival (OS) of the 85 patients was 22.1 months (95% CI: 12.9-31.3); the 1-, 2-, 3-, and 4-year OS rates were 70.9% (95% CI: 61.1-80.7%), 47.6% (36.8-58.4%), 37.7% (26.7-48.7%), and 22.7% (10.2-35.2%), respectively; and the 1-, 2-, 3-, and 4-year local recurrence rates were 8.2% (1.1-15.3%), 21.6% (9.3-33.9%), 33.4% (16.7-50.1%), and 33.4% (16.7-50.1%), respectively. In the meta-analysis and registry data, the 1-year OS for particle therapy, SBRT and 3D-CRT were 71.8% (95% CI: 64.6-77.8%), 59.2% (53.0-64.9%, p = 0.0573), and 47.2% (36.8-56.9%, p = 0.0004), respectively. The incidence of grade 3 or higher late non-hematological toxicity in the meta-analysis and registry data were 7.4-12% for particle therapy, 6.7-16.7% for SBRT, and 8.1-14.3% for 3D-CRT.

Conclusions: Particle therapy achieved a good therapeutic effect for ICC, and a meta-analysis indicated that particle therapy is a better treatment modality than SBRT and 3D-CRT.

查看原文本刊更多论文

颗粒治疗肝内胆管癌：一项多中心前瞻性注册研究，系统评价和荟萃分析。

2016年5月，一项前瞻性研究开始评估颗粒治疗肝内胆管癌（ICC）的有效性和安全性。为了比较治疗方式，我们还对文献数据进行了荟萃分析，并使用注册表数据进行了系统比较。方法：对2016年5月至2018年6月接受颗粒治疗的ICC患者进行登记。选取19篇文献（粒子治疗4篇，3D-CRT 8篇，SBRT 7篇）进行meta分析。结果：共登记85例，其中质子束治疗59例，碳治疗26例。85例患者的中位总生存期（OS）为22.1个月（95% CI: 12.9-31.3）；1 - 2 -, 3 -和4 OS利率分别为70.9% (95% CI: 61.1—-80.7%),47.6%(-58.4% - 36.8),37.7%(26.7 - -48.7%)和22.7%(10.2 - -35.2%),分别为;1年、2年、3年、4年局部复发率分别为8.2%（1.1 ~ 15.3%）、21.6%（9.3 ~ 33.9%）、33.4%（16.7 ~ 50.1%）、33.4%（16.7 ~ 50.1%）。在meta分析和注册数据中，颗粒治疗、SBRT和3D-CRT的1年OS分别为71.8% （95% CI: 64.6-77.8%）、59.2% （53.0-64.9%,p = 0.0573）和47.2% （36.8-56.9%,p = 0.0004）。在meta分析和注册数据中，3级或更高级别晚期非血液学毒性的发生率颗粒治疗为7.4-12%，SBRT为6.7-16.7%，3D-CRT为8.1-14.3%。结论：颗粒治疗对ICC有较好的治疗效果，meta分析显示颗粒治疗优于SBRT和3D-CRT。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Liver Cancer Medicine-Oncology

CiteScore

20.80

自引率

7.20%

发文量

审稿时长

16 weeks

期刊介绍： Liver Cancer is a journal that serves the international community of researchers and clinicians by providing a platform for research results related to the causes, mechanisms, and therapy of liver cancer. It focuses on molecular carcinogenesis, prevention, surveillance, diagnosis, and treatment, including molecular targeted therapy. The journal publishes clinical and translational research in the field of liver cancer in both humans and experimental models. It publishes original and review articles and has an Impact Factor of 13.8. The journal is indexed and abstracted in various platforms including PubMed, PubMed Central, Web of Science, Science Citation Index, Science Citation Index Expanded, Google Scholar, DOAJ, Chemical Abstracts Service, Scopus, Embase, Pathway Studio, and WorldCat.